STOCK TITAN

Kiniksa Pharmaceuticals International, plc Stock Price, News & Analysis

KNSA Nasdaq

Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.

Kiniksa Pharmaceuticals International, plc (KNSA) is a clinical and commercial-stage biopharmaceutical company pioneering immune-modulating therapies for autoimmune and cardiovascular diseases. This dedicated news hub provides investors, researchers, and healthcare professionals with timely updates on corporate developments and scientific advancements.

Access the most comprehensive collection of Kiniksa news including regulatory milestones, clinical trial results, and strategic partnerships. Our curated feed delivers essential updates on ARCALYST commercialization progress, abiprubart development phases, and pipeline expansion efforts – all critical for informed decision-making in biopharma investing.

Key content categories cover FDA submissions, research collaborations, financial performance, and therapy access initiatives. The centralized format ensures efficient tracking of Kiniksa's progress in addressing complex inflammatory conditions through targeted immune modulation.

Bookmark this page for streamlined monitoring of KNSA's evolving position in autoimmune therapeutics. Verify information accuracy through direct links to official company communications and peer-reviewed clinical data sources.

Rhea-AI Summary

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:40 a.m. Eastern Time.

The presentation will be live-streamed on Kiniksa's website under the Investors & Media section. A replay will be available approximately 48 hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
-
Rhea-AI Summary

Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags

FAQ

What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?

The current stock price of Kiniksa Pharmaceuticals International, plc (KNSA) is $27.78 as of May 5, 2025.

What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?

The market cap of Kiniksa Pharmaceuticals International, plc (KNSA) is approximately 1.6B.
Kiniksa Pharmaceuticals International, plc

Nasdaq:KNSA

KNSA Rankings

KNSA Stock Data

1.57B
71.20M
4.01%
89.92%
4.13%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United Kingdom
LONDON